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TORC1-regulated protein kinase Npr1 
phosphorylates Orm to stimulate complex 
sphingolipid synthesis
Mitsugu Shimobayashi, Wolfgang Oppliger, Suzette Moes, Paul Jenö, and Michael N. Hall
Biozentrum, University of Basel, 4056 Basel, Switzerland
ABSTRACT The evolutionarily conserved Orm1 and Orm2 proteins mediate sphingolipid ho-
meostasis. However, the homologous Orm proteins and the signaling pathways modulating 
their phosphorylation and function are incompletely characterized. Here we demonstrate 
that inhibition of nutrient-sensitive target of rapamycin complex 1 (TORC1) stimulates Orm 
phosphorylation and synthesis of complex sphingolipids in Saccharomyces cerevisiae. TORC1 
inhibition activates the kinase Npr1 that directly phosphorylates and activates the Orm 
proteins. Npr1-phosphorylated Orm1 and Orm2 stimulate de novo synthesis of complex 
sphingolipids downstream of serine palmitoyltransferase. Complex sphingolipids in turn stim-
ulate plasma membrane localization and activity of the nutrient scavenging general amino 
acid permease 1. Thus activation of Orm and complex sphingolipid synthesis upon TORC1 
inhibition is a physiological response to starvation.
INTRODUCTION
Target of rapamycin (TOR) is a highly conserved serine/threonine ki-
nase that controls cell growth in response to nutrients. TOR is found 
in two structurally and functionally distinct complexes termed TOR 
complex 1 (TORC1) and TORC2 (Loewith et al., 2002; Wedaman 
et al., 2003; Wullschleger et al., 2006). Rapamycin-sensitive TORC1 
controls cell growth in response to nutrients by promoting anabolic 
processes such as translation and ribosome biogenesis and by an-
tagonizing catabolic processes such as autophagy and mRNA deg-
radation (De Virgilio and Loewith, 2006; Loewith and Hall, 2011). In 
yeast, TORC1 also regulates the abundance and activity of amino 
acid permeases. When cells are grown in nutrient-rich medium, 
TORC1 maintains several highly specific amino acid permeases—for 
example, the tryptophan permease Tat2 (Beck et al., 1999). On 
TORC1 inhibition, by rapamycin treatment or nutrient deprivation, 
the specific permeases are turned over and replaced by the general 
amino acid permease 1 (Gap1). Replacement of several distinct per-
meases by Gap1 enables cells to optimize nutrient uptake and en-
ergy consumption during nutrient stress (Roberg et al., 1997; Beck 
et al., 1999). TORC1 inhibits export and stability of Gap1 via phos-
phorylation and inhibition of the serine/threonine kinase Npr1 
(Schmidt et al., 1998; De Craene et al., 2001). However, the mole-
cular mechanism by which Npr1 promotes Gap1 export and stability 
remains incompletely characterized.
Sphingolipids are structural components of membranes and 
signaling molecules (Hannun and Obeid, 2008). The first and rate-
limiting step in de novo synthesis of sphingolipids is the condensa-
tion of l-serine and fatty acid-CoA at the endoplasmic reticulum (ER) 
to produce long-chain bases (LCBs; Figure 1). This reaction is cata-
lyzed by serine palmitoyltransferase (SPT), a multiprotein complex 
consisting of Lcb1, Lcb2, and Tsc3 (Nagiec et al., 1994; Gable et al., 
2000). LCBs, including dihydrosphingosine (DHS) and phytosphin-
gosine (PHS), are in turn acylated to form ceramides (Guillas et al., 
2001; Schorling et al., 2001; Vallee and Riezman, 2005). Ceramides 
are transported to the Golgi for further modification to generate 
complex sphingolipids such as inositol phosphorylceramide (IPC) 
and mannosyl IPC (MIPC). In yeast, LCBs transiently increase in re-
sponse to heat stress and are required for the response to this stress 
(Dickson et al., 1997; Jenkins et al., 1997; Skrzypek et al., 1999; Zhang 
et al., 2001; Meier et al., 2006). De novo sphingolipid synthesis is also 
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Here we show that the TORC1 indeed controls the Orm proteins 
and consequently sphingolipid synthesis independent of TORC2. 
Rapamycin-triggered Orm phosphorylation does not affect SPT ac-
tivity but instead increases de novo synthesis specifically of complex 
sphingolipids. Thus, whereas TORC2 inhibition reduces sphingo-
lipid synthesis, TORC1 inhibition stimulates synthesis of complex 
sphingolipids downstream of SPT. TORC1 controls Orm phosphory-
lation via the starvation-activated kinase Npr1. Npr1 phosphoryla-
tion of Orm stimulates de novo synthesis of complex sphingolipids 
and appearance of Gap1 at the PM. Thus TORC1 controls Orm and 
sphingolipid synthesis as a part of an adaptive response to nutrient 
stress.
RESULTS
TORC1 inhibition stimulates Orm phosphorylation
Two phosphoproteomic studies suggested that Orm1 phosphoryla-
tion increases upon TORC1 inhibition (rapamycin treatment; Huber 
et al., 2009; Soulard et al., 2010). To confirm this observation and to 
investigate whether rapamycin also affects Orm2 phosphorylation, 
we examined Orm phosphorylation by immunoblotting cellular ex-
tracts resolved by phospho–affinity gel electrophoresis (Kinoshita 
et al., 2006). Rapamycin increased phosphorylation of both Orm1 
and Orm2 in a TORC1-sensitive manner (Figure 2, A and B, and 
Supplemental Figure S1A). Inactivation of TORC1 by nitrogen star-
vation also triggered Orm phosphorylation, suggesting that the ef-
fect of rapamycin is physiologically relevant (Figure 2C and Supple-
mental Figure S1B). Conversely, cycloheximide (CHX), which 
increases intracellular pools of free amino acids and thereby acti-
vates TORC1 (Binda et al., 2009), decreased Orm phosphorylation 
(Figure 2D). Thus TORC1 inhibits phosphorylation of both Orm1 
and Orm2 in response to nutrients.
TORC1 does not control SPT activity
The finding that TORC1 controls Orm phosphorylation prompted us 
to investigate whether TORC1 regulates SPT. Myriocin triggers Orm 
phosphorylation, dissociation of Orm oligomers, and reduced Orm2 
cortical-ER (cER) localization, thereby inhibiting Orm. Orm inhibition 
in turn leads to SPT activation (Breslow et al., 2010). We asked 
whether rapamycin-triggered Orm phosphorylation has similar ef-
fects. Contrary to what was observed with myriocin (Breslow et al., 
2010), rapamycin treatment had only mild effect on the integrity of 
Orm oligomers and no effect on cER localization of GFP-Orm (Figure 
3, A and B, and Supplemental Figure S2A). Furthermore, TORC1 
inhibition had no effect on the interaction of Orm with SPT or 
Sac1 (phospatidylinositol-4-phosphate phosphatase; Supplemental 
Figure S2, B and C). Orm had been shown to associate with Sac1, 
although the functional significance of this interaction is unknown 
(Breslow et al., 2010). Rapamycin had no effect on de novo synthesis 
of LCBs and ceramides in vivo (Figure 3C). Finally, rapamycin had no 
effect on SPT activity, as measured by incorporation of [3H]serine 
into LCBs in vitro (Figure 3D). Thus TORC1 does not regulate SPT 
activity, although TORC1 inhibition causes Orm phosphorylation.
TORC1 negatively controls synthesis of complex 
sphingolipids
On measuring de novo sphingolipid synthesis by [3H]serine incorpo-
ration, we unexpectedly observed a ∼60% increase in IPCs and in 
MIPCs in rapamycin-treated cells (Figure 3, C and E, and Supple-
mental Figure S3A). The increase in complex sphingolipids was not 
due to increased uptake of [3H]serine (Figure 3F and Supplemental 
Figure S3A) or decreased turnover of IPCs and MIPCs (Supplemental 
Figure S3B). Decreased turnover was ruled out because rapamycin 
required for nutrient stress responses, including appearance of Gap1 
at the plasma membrane (PM; Lauwers et al., 2007), but it is unknown 
whether nutrients control synthesis of sphingolipids.
Several lines of evidence suggest that sphingolipid synthesis and 
the TOR signaling pathway are functionally linked in yeast. A screen 
for suppressors of a csg2 mutation, conferring a defect in complex 
sphingolipid synthesis, identified TOR2 and AVO3/TSC10, both of 
which encode components of TORC2 (Beeler et al., 1998). Con-
versely, a screen for high-copy suppressors of a TOR2 defect yielded 
SUR1, encoding a subunit of MIPC synthetase (Helliwell et al., 1998). 
Aronova et al. (2008) subsequently showed that TORC2 positively 
regulates ceramide production. More recent findings suggest that 
TORC2 mediates sphingolipid homeostasis via Orm proteins 
(Breslow et al., 2010; Roelants et al., 2011). Thus at least TORC2 
appears to control sphingolipids synthesis.
The Orm proteins are an evolutionarily conserved family of ER 
transmembrane proteins that mediate sphingolipid homeostasis 
(Breslow et al., 2010). In yeast and likely in mammals, an Orm1–
Orm2 complex binds and inhibits SPT (Figure 1; Breslow et al., 
2010; Han et al., 2010). Orm1 and Orm2 are phosphorylated and 
thereby inhibited in response to sphingolipid depletion caused, 
for example, by treatment with a low concentration of the SPT in-
hibitor myriocin/ISP-1. Myriocin induces phosphorylation of Ser-
51, Ser-52, or Ser-53 in Orm1 and Ser-46, Ser-47, or Ser-48 in 
Orm2 (Breslow et al., 2010; Roelants et al., 2011). On Orm inhibi-
tion, SPT is activated, and cells restore sphingolipid levels (Breslow 
et al., 2010). Sphingolipid depletion by myriocin activates TORC2 
and its downstream AGC kinase Ypk1, which directly phosphory-
lates and inhibits Orm (Roelants et al., 2011; Berchtold et al., 
2012). Thus TORC2 stimulates sphingolipid synthesis. Orm2 is 
also transiently phosphorylated and inactivated by Ypk1 in re-
sponse to heat stress (Sun et al., 2012), causing an increase in 
LCBs required for the heat stress response (Dickson et al., 1997; 
Jenkins et al., 1997). In addition, TORC1 inhibition (rapamycin 
treatment) leads to Orm1 phosphorylation, but at sites distinct 
from those phosphorylated upon TORC2 activation (Huber et al., 
2009; Soulard et al., 2010). This suggests that TORC1 signaling, 
independent of TORC2, also regulates Orm and sphingolipid 
metabolism.
FIGURE 1: Schematic diagram of de novo sphingolipid biosynthesis 
in yeast.
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The accumulation of elevated levels of LCBs and ceramides is con-
sistent with the previously described role of Orm as a negative regu-
lator of SPT but can also be explained by loss of Orm-dependent 
synthesis of complex sphingolipids downstream of SPT. These find-
ing suggest that Orm has two separate functions in sphingolipid 
metabolism—inhibition of SPT and activation of complex sphingo-
lipid synthesis.
TORC1 inhibits complex sphingolipid synthesis 
via inhibition of Orm
Does TORC1 control synthesis of complex sphingolipids via Orm 
phosphorylation? To answer this question, we first determined the 
rapamycin-dependent phosphorylation sites in Orm1 and Orm2. 
Previous studies describing the rapamycin sensitive phosphopro-
teome reported only Orm1 phosphorylation (Huber et al., 2009; 
Soulard et al., 2010). FLAG-Orm proteins were purified from cells 
grown in the presence or absence of rapamycin, trypsinized, and 
analyzed by mass spectrometry. Confirming previous studies, ra-
pamycin induced single, double, or triple phosphorylation of Orm1 
on Ser-29, Ser-32, Ser-34, Ser-35, and/or Ser-36. We found that ra-
pamycin also induced single or double phosphorylation of Orm2 
on Ser-9, Ser-15, Thr-18, Ser-22, Ser-29, and/or Ser-31 (Figure 4, 
A and B, and Supplemental Figure S4, A and B). These Orm1 
and Orm2 phosphorylation sites are distinct from the sites that are 
still enhanced IPC and MIPC levels in cells deleted for ISC1, encod-
ing inositol phosphosphingolipid phospholipase that cleaves IPCs 
and MIPCs (Figure 1 and Supplemental Figure S3B). The ∼60% in-
crease in de novo synthesis of complex sphingolipids was confirmed 
by measuring incorporation of [3H]DHS (Figure 3G and Supplemen-
tal Figure S3C). Because DHS enters the sphingolipid biosynthesis 
pathway below SPT, the rapamycin-induced increase observed upon 
[3H]DHS labeling suggests that TORC1 inhibition stimulates com-
plex sphingolipid synthesis at a later step than SPT. Thus TORC1 
inhibition triggers de novo synthesis of complex sphingolipids.
Orm is required for de novo synthesis 
of complex sphingolipids
The foregoing indicates that TORC1 inhibition leads to Orm phos-
phorylation and enhanced synthesis of complex sphingolipids. 
Does Orm have a role in the synthesis of complex sphingolipids? 
To address this question, we examined the effect of loss of Orm1 
and Orm2 on synthesis of complex sphingolipids. An orm1∆ orm2∆ 
strain displayed significantly reduced amounts of complex sphin-
golipids (IPCs and MIPCs), as measured by incorporation of [3H]
serine (Figure 3H), as well as of [3H]DHS (Supplemental Figure S3C). 
This suggests that Orm has a positive role in the synthesis of com-
plex sphingolipids downstream of SPT. The orm1∆ orm2∆ strain 
also exhibited elevated levels of LCBs and ceramides (Figure 3H). 
FIGURE 2: TORC1 negatively regulates Orm phosphorylation. (A, B) Immunoblot analysis of Orm1 (A) and Orm2 (B) 
phosphorylation in wild-type (WT), tor1∆, and rapamycin-resistant TOR (TORRR) cells. Growing cells expressing HA-Orm 
proteins were treated with rapamycin (200 ng/ml) for 1 h. The total lysates were resolved by a phospho–affinity gel and 
conventional SDS–PAGE gels and analyzed by Immunoblot against HA and actin, a loading control. TB50a was used as a 
mock control. (C) Immunoblot analysis of Orm phosphorylation upon nitrogen starvation. Growing cells expressing 
HA-Orm1 or HA-Orm2 were shifted to nitrogen-free medium (SD-N) and cultured for 1 h. The total lysates were 
analyzed as described in A and B. (D) Immunoblot analysis of Orm phosphorylation after 1-h treatment of cycloheximide 
(CHX, 25 μg/ml) with or without cotreatment of rapamycin. The total lysates prepared from FLAG-Orm1– or FLAG-
Orm2–expressing cells were analyzed as in A and B, except that a FLAG antibody was used.
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FIGURE 3: TORC1 inhibition increases de novo synthesis of complex sphingolipids downstream of SPT. 
(A) Coimmunoprecipitation analysis of Orm1 and Orm2. Immunoprecipitation of FLAG-Orm1 and Orm2 was performed 
as described in Materials and Methods. Immunoprecipitated proteins were analyzed by Immunoblot as in Figure 2. 
(B) Confocal microscopic analyses of GFP-Orm2 with (+) or without (–) 200 ng/ml rapamycin treatment for 1 h. Sec63-
mCherry was used as a marker for ER localization. Arrows indicate cER. (C) TLC analysis of [3H]serine-labeled 
sphingolipids. Growing cells were treated with (+) or without (–) 200 ng/ml rapamycin for 1 h and labeled with [3H]serine 
for 30 min. The extracted lipids were subjected to mild alkaline hydrolysis and separated by TLC. Sphingolipid profiles of 
myriocin-treated WT cells and csg2∆ cells were used to identify sphingolipids and IPCs/MIPCs, respectively. Ceramides, 
DHS, and PHS were identified by mobility of respective standard lipid species on TLC. DHS, dihydrosphingosine; IPCs, 
inositol phosphorylceramides; MIPCs, mannosyl IPCs; PHS, phytosphingosine. *Unidentified myriocin-insensitive lipids. 
(D) in vitro SPT assay. SPT activity was measured by incorporation of [3H]serine into 3-ketosphinganine as described in 
Materials and Methods. (E) Quantification of [3H]serine-labeled MIPCs (mean ± SEM) in Figure 3C. *p < 0.05. (F) Serine 
uptake assay in rapamycin-treated and untreated cells. Cells were treated with rapamycin and labeled with [3H]serine as 
in C. Incorporation of [3H]serine was measured by a scintillation counter. Data are presented as mean ± SEM. 
(G) Quantification of [3H]DHS-labeled MIPCs (mean ± SEM). Cells were treated with rapamycin and labeled with [3H]DHS 
as in C. **p < 0.01. (H) TLC analysis of [3H]serine-labeled sphingolipids in WT and orm1∆orm2∆ cells. The [3H]serine 
labeling, lipid preparation, and TLC were performed as in C. *Unidentified myriocin-insensitive lipids.
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FIGURE 4: TORC1 inhibition promotes de novo complex sphingolipid synthesis via Orm phosphorylation. (A, B) An 
N-terminal peptide sequence of Orm1 (A) and Orm2 (B). The phosphodeficient mutations are highlighted in red. 
(C) Immunoblot analysis of Orm1 phosphorylation in phosphodeficient mutants of Orm1 upon rapamycin treatment. 
Cells expressing FLAG-Orm1 summarized in A were treated with (+) or without (–) rapamycin (200 ng/ml) for 1 h. The 
total lysates were analyzed as in Figure 2D. (D) Immunoblot analysis of Orm2 phosphorylation in phosphodeficient 
mutants of Orm2 upon rapamycin treatment. Cells expressing FLAG-Orm2 summarized in B were treated with (+) or 
without (–) rapamycin (200 ng/ml) for 1 h. (E, F) Immunoblot analysis of Orm1 (E) and Orm2 (F) phosphorylation in 
phosphodeficient mutants upon myriocin treatment. Same cells as in C and D were treated with (+) or without (–) 
myriocin (500 ng/ml) for 1 h. (G) TLC analysis of [3H]serine-labeled IPCs and MIPCs in WT (ORM1 ORM2) and Ala 
mutants in rapamycin-responsive sites (orm1-5A orm2-7A). Labeling and TLC analysis were performed as in Figure 3C, 
and rapamycin-triggered increase of MIPCs was quantified in a bar graph (mean ± SEM). *p < 0.05. (H) Phosphodeficient 
mutant alleles of Orm proteins were analyzed for growth on SD plates in the presence of myriocin. The plates were 
incubated at 30ºC for 3 d. (I) in vitro SPT assay. SPT activity was measured by incorporation of [3H]serine into 
3-ketosphinganine as described in Materials and Methods.
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Npr1-mediated Orm phosphorylation enhances Gap1 
localization and activity
What is the physiological significance of Npr1-mediated Orm phos-
phorylation and complex sphingolipid synthesis? Npr1 promotes 
PM localization and stabilization of the general amino acid permease 
Gap1 in response to nutrient limitation (De Craene et al., 2001). Fur-
thermore, Gap1 PM localization and stabilization require de novo 
synthesis of sphingolipids, most likely ceramides or complex sphin-
golipids (Lauwers et al., 2007). These findings suggest that Npr1 is 
activated in nutrient-deprived (TORC1-inhibited) cells to increase de 
novo synthesis of complex sphingolipids and thereby to stabilize 
Gap1 permease at the PM. To investigate this possibility, we moni-
tored Gap1 localization by subcellular fractionation of cells grown in 
nitrogen-poor conditions. Gap1 from orm1-5A orm2-7A cells was 
found mainly in endosomal fractions, whereas Gap1 from wild-type 
cells was found largely in PM fractions (Figure 6, A and B). We also 
visualized Gap1-GFP in live cells grown in a poor nitrogen source. 
Consistent with the subcellular fractionation, PM localization of 
Gap1-GFP was mildly reduced in orm1-5A orm2-7A cells compared 
with wild-type cells (Figure 6, C and D). To determine the functional 
consequence of reduced Gap1 at the PM, we assayed uptake of the 
Gap1 substrate citrulline. The rate of [14C]citrulline uptake was mildly 
but significantly reduced in orm1-5A orm2-7A cells compared with 
wild-type cells (Figure 6E). Thus Npr1-mediated Orm phosphoryla-
tion and thereby complex sphingolipid synthesis promote Gap1 PM 
localization and activity in response to nutrient limitation.
DISCUSSION
Here we report that TORC1 inhibition stimulates Orm phosphoryla-
tion and de novo synthesis of complex sphingolipids (Figure 7). On 
TORC1 inhibition by rapamycin treatment or nutrient limitation, 
Npr1 phosphorylates and activates Orm1 and Orm2, which in turn 
promotes synthesis of complex sphingolipids downstream of SPT. 
The raison d’être of this response appears to be to alter cell physiol-
ogy to allow the cell to better cope with nutrient limitation, as com-
plex sphingolipids are required for up-regulation of the nutrient-
scavenging permease Gap1. The negative regulation of sphingolipid 
synthesis by TORC1 described here is distinct from the previously 
reported positive regulation of sphingolipids by TORC2. On TORC2 
activation by myriocin treatment or sphingolipid depletion, Ypk1 
phosphorylates and inhibits the Orm1–Orm2, complex which in turn 
results in activation of SPT and synthesis of LCBs to restore sphingo-
lipid levels (Roelants et al., 2011). We note that the orm1-5A 
orm2-7A mutant phenocopies the rapamycin resistance of an npr1 
mutant, whereas the orm1-3A orm2-3A mutant phenocopies the 
rapamycin hypersensitivity of a ypk1 mutant (Gelperin et al., 2002), 
further suggesting that TORC1 and TORC2 have distinct roles in the 
control of Orm.
We propose a new function for the Orm proteins in the regula-
tion of sphingolipid biosynthesis. Breslow et al. (2010) examined 
genetic interactions between ORM2 and ER-related functions. They 
reported that an ORM2 deletion suppresses defects in ER-localized 
sphingolipid biosynthesis caused by a lcb1, lcb2, tsc3, tsc10, lcb4, 
sur2, lag1, or lac1 mutation (Figure 1). However, they also found, but 
without further mention, that an ORM2 deletion exacerbates the 
effect of an aur1, csg2, csh1, or sur1 mutation defective in complex 
sphingolipid synthesis. These genetic data suggest that Orm has 
two distinct functions in sphingolipid metabolism. The first, as de-
scribed previously (Breslow et al., 2010; Han et al., 2010), is to an-
tagonize SPT. Indeed, Orm1–Orm2 directly binds and inhibits SPT in 
the ER. The second Orm function, as described here, is to promote 
the synthesis of complex sphingolipids in the Golgi. The molecular 
phosphorylated in response to myriocin treatment (see Introduc-
tion). Serine-to-alanine mutation of the five serines in Orm1 (orm-
-5A) abolished rapamycin-triggered phosphorylation of Orm1 
(Figure 4C). Similarly, conversion of the six Ser/Thr sites in Orm2 in 
combination with the previously identified phosphosite Thr-36 
(Breslow et al., 2010) to alanine (orm2-7A) prevented rapamycin-in-
duced phosphorylation of Orm2 (Figure 4D). Orm1-5A and Orm-
-7A were still phosphorylated in response to myriocin (Figure 4, E 
and F). Conversely, mutation of the sites in Orm1 (orm1-3A) and 
Orm2 (orm2-3A) that are phosphorylated in response to myriocin 
had no effect on rapamycin-induced phosphorylation (Figure 4, C 
and D). These findings suggest that TORC1 (rapamycin) controls 
Orm phosphorylation and sphingolipid synthesis via a mechanism 
distinct from that of TORC2 (myriocin).
To investigate whether rapamycin-triggered synthesis of com-
plex sphingolipids is mediated by Orm phosphorylation, we exam-
ined the sphingolipid profile in orm1-5A orm2-7A cells. Rapamycin 
failed to stimulate synthesis of complex sphingolipids in orm1-5A 
orm2-7A cells (Figure 4G), as measured by incorporation of [3H]ser-
ine. Furthermore, consistent with the foregoing findings that TORC1 
(rapamycin) and TORC2 (myriocin) independently affect Orm phos-
phorylation and sphingolipid synthesis (Figure 4, B–G), orm1-5A 
and orm2-7A had no effect on growth inhibition by myriocin (Figure 
4H and Supplemental Figure S5) or on SPT activity as measured in 
vitro (Figure 4I). Thus TORC1 inhibition triggers Orm phosphoryla-
tion and thereby activates Orm to promote de novo synthesis of 
complex sphingolipids downstream of SPT.
TORC1 mediates Orm phosphorylation and complex 
sphingolipid synthesis via Npr1
What is the TORC1-inhibited (rapamycin-stimulated) kinase that 
phosphorylates Orm? TORC1 inhibits the Ser/Thr kinase Npr1 
(Schmidt et al., 1998), and a recent phosphoproteome analysis sug-
gested that Orm1 is phosphorylated in an Npr1-dependent manner 
(MacGurn et al., 2012). The observation that an orm1-5A orm2-7A 
mutant phenocopies an npr1∆ mutant with regard to rapamycin re-
sistance further suggested that Npr1 and Orm are functionally re-
lated (Figure 5A; Schmidt et al., 1998; De Craene et al., 2001; 
MacGurn et al., 2012). Thus we investigated whether Npr1 is the 
rapamycin-triggered kinase that phosphorylates Orm. Rapamycin 
failed to stimulate Orm phosphorylation in npr1∆ cells or in cells 
expressing a kinase-dead version of Npr1 (npr1-K467R; Figure 5B 
and Supplemental Figures S4B and S6, A and B). Rapamycin also 
failed to stimulate Orm phosphorylation in sit4∆ cells that lack the 
catalytic subunit of the PP2A phosphatase responsible for Npr1 de-
phosphorylation and activation downstream of TORC1 (Supplemen-
tal Figure S6C; Arndt et al., 1989; Schmidt et al., 1998). To deter-
mine whether Npr1 phosphorylates Orm directly, we performed an 
in vitro kinase assay with native or recombinant Orm and Npr1 im-
munopurified from rapamycin-treated cells. Npr1, but not kinase-
dead Npr1-K467R, phosphorylated native and recombinant Orm1 
and Orm2 but not recombinant Orm1-5A and Orm2-7A (Figure 5, 
C–G). Thus Npr1 directly phosphorylates Orm1 and Orm2 down-
stream of TORC1.
The finding that Npr1 mediates rapamycin-induced phosphory-
lation of Orm suggests that Npr1 controls complex sphingolipid 
synthesis. To investigate this possibility, we examined incorporation 
of [3H]serine or [3H]DHS in rapamycin-treated npr1∆ cells (Figure 5, 
H and I). Rapamycin failed to stimulate incorporation of either label 
in Npr1-deficient cells. Thus TORC1 inhibition activates Npr1 ki-
nase, which directly phosphorylates Orm to promote de novo syn-
thesis of complex sphingolipids.
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FIGURE 5: TORC1 mediates Orm phosphorylation and complex sphingolipid synthesis via Npr1. (A) WT, npr1∆, and 
phosphodeficient mutant alleles of Orm proteins were analyzed for growth on SD plates in the presence of rapamycin. 
The plates were incubated at 30ºC for 3 d. (B) Immunoblot analysis of Orm phosphorylation in rapamycin-treated WT or 
npr1∆ cells. Cells expressing HA-Orm1 or HA-Orm2 were treated with (+) or without (–) rapamycin (200 ng/ml) for 1 h. 
The total lysates were analyzed as in Figure 2A. (C–E) In vitro kinase assay of GST-Npr1 toward native Flag-Orm1 and 
-Orm2 purified from yeast (C) or N-terminal–truncated recombinant GST-Orm1 (D) and GST-Orm2 (E) as described in 
Materials and Methods. kd, kinase dead Npr1-K467R. (F, G) In vitro kinase assay of GST-Npr1 toward recombinant Ala 
mutant alleles of GST-Orm1 (F) and GST-Orm2 (G). (H, I) TLC analysis of [3H]serine (H)– or [3H]DHS (I)–labeled IPCs and 
MIPCs in WT and npr1∆ cells. Growing cells were treated with (+) or without (–) rapamycin for 1 h and labeled with [3H]
serine (H) or [3H]DHS (I) for 30 min. The extracted lipids were subjected to mild alkaline hydrolysis and separated by 
TLC. The bar graphs show quantification of rapamycin-triggered increase of MIPCs (mean ± SEM). *p < 0.05, **p < 0.01.
ER-to-Golgi flux of ceramides and/or enzymes required for synthesis 
of complex sphingolipids in the Golgi. Third, Orm may activate/
modify substrates or enzymes in the ER that are subsequently re-
quired for IPC synthesis in the Golgi. For example, Orm may acti-
vate Sac1. Sac1 is an ER phosphatidylinositol-4-phosphate phos-
phatase required for synthesis of complex sphingolipids in the Golgi 
(Brice et al., 2009). Of interest, sac1∆ cells are rapamycin hypersen-
sitive, indicating a functional interaction between Sac1 and TORC1 
(Banuelos et al., 2010), and Orm physically interacts with Sac1 
mechanism by which Orm promotes synthesis of complex sphingo-
lipids in the Golgi is unknown, although it may be indirect, as Orm 
has been reported to be exclusively in the ER (Breslow et al., 2010). 
One possible mechanism is that ER-localized Orm increases synthe-
sis of complex sphingolipid precursors such as ceramides, since 
Orm proteins were shown recently to physically associate with the 
ceramide synthetase Lac1 (Liu et al., 2012). However, this seems un-
likely since orm1∆ orm2∆ cells accumulate ceramides (Figure 3H). 
A second potential mechanism is that ER-localized Orm increases 
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FIGURE 6: Npr1-mediated Orm phosphorylation stimulates Gap1 PM localization and activity. 
(A) Subcellular fractionation analysis of Gap1 in Flag-ORM1 Flag-ORM2 (WT) and Flag-orm1-5A 
Flag-orm2-7A (orm1-5A orm2-7A) cells. Cells were grown in SD media and shifted to urea 
media. After 2 h of incubation, harvested cells were lysed and fractionated by ultracentrifugation 
on continuous 20–60% (wt/wt) sucrose gradients. The fractions were resolved by SDS–PAGE and 
analyzed by immunoblot against Pma1 (a plasma membrane marker), Gap1, and Pep12 (an 
endosomal marker). (B) Quantification of relative Gap1 in A. Data are presented as means ± 
SEM. (C) Microscopic analysis of Gap1-GFP in Flag-ORM1 Flag-ORM2 (WT) and Flag-orm1-5A 
Flag-orm2-7A (orm1-5A orm2-7A) cells. Cells were cultured in SD-N supplemented with urea for 
2 h and analyzed by fluorescence microscopy. (D) Quantification of relative expression of PM 
Gap1-GFP. The intensities of PM GFP signals were normalized to those of total GFP signals from 
at least 50 cells. Data are presented as means ± SEM. ***p < 10−9. (E) The [14C]citrulline uptake 
in Flag-ORM1 Flag-ORM2 (WT) and Flag-orm1-5A Flag-orm2-7A (orm1-5A orm2-7A) cells. Cells 
were cultured in SD-N supplemented with urea and assayed for [14C]citrulline incorporation as 
described in Materials and Methods. The relative uptake of [14C]citrulline ± SEM respect to WT 
cells is shown. *p < 0.05, **p < 0.01.
Another possibility is that the cell ceases to 
use LCBs for production of LCB phosphates 
and uses the resulting liberated LCBs to 
produce complex sphingolipids. In support 
of this possibility, rapamycin treatment stim-
ulates vacuolar degradation of the LCB ki-
nase Lcb4 (Iwaki et al., 2007).
Liu et al. (2012) recently also reported 
regulation of Orm1 phosphorylation by 
TORC1-PP2A-Npr1 signaling. However, un-
like our study, they did not observe regula-
tion of Orm2 phosphorylation by TORC1-
PP2A-Npr1 signaling. This apparent 
discrepancy is likely due to the different 
methods used in the two studies to assay 
Orm2 phosphorylation. Whereas they as-
sayed Orm phosphorylation by mobility shift 
in conventional SDS–PAGE (Liu et al., 2012), 
we used phospho–affinity gels and mass 
spectrometry. Our Npr1 kinase assay in vitro 
further demonstrates that both Orm1 and 
Orm2 are downstream of TORC1-Npr1 
(Figure 5, C–G). Another important differ-
ence in the two studies is that Liu et al. did 
not distinguish myriocin- and rapamycin-
triggered Orm phosphorylation and thus 
did not investigate a potential role of ra-
pamycin-triggered Orm phosphorylation in 
sphingolipid synthesis.
We show that TORC1 inhibition stimu-
lates Gap1 permease activity via Npr1-
mediated phosphorylation of Orm and 
up-regulation of complex sphingolipid syn-
thesis. Complex sphingolipids enhance sta-
bility of Gap1 at the PM (Lauwers et al., 
2007). Two recent studies suggest that 
TORC1 inhibition stimulates Gap1 sorting 
to the PM by Npr1-mediated phosphoryla-
tion of Aly1/2 and Bul1/2 α-arrestin proteins 
(O’Donnell et al., 2010; Merhi and Andre, 
2012). Aly1 and Aly2 stimulate transport of 
Gap1 from endosomal compartments to the 
trans-Golgi network and/or the PM. Bul1 
and Bul2 are adaptor proteins for the Rsp5 
ubiquitin ligase, which promotes Gap1 
ubiquitylation and turnover. Npr1 phospho-
rylates and inhibits Bul1/2 to inhibit Gap1 
ubiquitylation and turnover. Moreover, 
TORC1 inhibition also stimulates Gap1 tran-
scription via the GATA factors Gln3 and 
Gat1 (Beck and Hall, 1999; Cardenas et al., 1999; Hardwick et al., 
1999). Thus there are four separate effector pathways via which 
TORC1 inhibition up-regulates Gap1. This may explain why the 
orm1-5A orm2-7A mutant, in which only one of the four pathways is 
inhibited, displays only a mild effect on Gap1 activity.
The human ORM orthologue, ORMDL3, is a risk factor for child-
hood asthma (Moffatt et al., 2007), type 1 diabetes (Barrett et al., 
2009), ulcerative colitis (McGovern et al., 2010), and Crohn’s disease 
(Barrett et al., 2008). It would be of interest to determine whether 
mammalian TOR (mTOR) has a role in ORMDL3 regulation, although 
Npr1 has no obvious orthologue in humans and the Npr1 target 
sites in Orm are not conserved. mTOR may have novel physiological 
(Breslow et al., 2010; Supplemental Figure S2C). The last two pos-
sibilities are supported by the observation that orm1∆ orm2∆ cells 
are defective in conversion of ceramides to IPCs (Figure 3H and 
Supplemental Figure S3C). Further work is required to elucidate the 
molecular mechanism by which Orm proteins regulate complex 
sphingolipid synthesis.
TORC1 inhibition stimulates synthesis of complex sphingolipids 
without stimulating SPT and de novo synthesis of LCBs and cer-
amides as precursors. How does the cell sustain synthesis of com-
plex sphingolipids upon TORC1 inhibition? The increase in complex 
sphingolipids could be merely a transient response that uses exist-
ing pools of LCBs and ceramides for adaptation to starvation. 
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FIGURE 7: Model of regulation of sphingolipid synthesis by TORC1 
and TORC2 signaling. FA-CoA, fatty acid-CoA.
anti-mouse immunoglobulin G (IgG; Pierce, Rockford, IL), HRP-
conjugated anti-goat IgG (Thermo Scientific, Waltham, MA), 
and HRP-conjugated anti-rabbit IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA).
Phospho–affinity gel electrophoresis
Yeast cells were resuspended in lysis buffer (Tris-buffered saline 
[TBS] containing 15% glycerol, 0.5% Tween-20, phosphatase inhibi-
tor mixture [PPi: 10 mM NaF, 10 mM NaN3, 10 mM p-nitrophenyl 
phosphate, 10 mM sodium pyrophosphate, and 10 mM ß-glycero-
phosphate], 1 mM phenylmethylsulfonyl fluoride, and protease in-
hibitor cocktails [Pi:EDTA-free Complete; Roche, Indianapolis, IN]). 
The cells were broken by a Fastprep (45 s ×5; 3-min interval on ice) 
at 4°C with glass beads. Unbroken cells and debris were removed 
by centrifugation at 500 × g for 10 min, and the supernatant 
containing 10 μg of protein was used for SDS–PAGE analysis. For 
phospho–affinity gels, the gels were run at 70 V constant for 2.5 h, 
rinsed twice for 5 min in transfer buffer containing 1 mM EDTA, and 
rinsed twice more for 5 min in transfer buffer without EDTA before 
transfer. Gel-to-gel differences in band pattern are due to variabil-
ity in phospho–affinity gel resolution as described in Breslow et al. 
(2010).
Fluorescence microscopy
For GFP-Orm localization, cells were cultured to early log phase 
and treated with rapamycin (final concentration, 200 ng/ml) for 
1 h. The fluorescence signals were observed using an inverted 
microscope (IX70; Olympus, Tokyo, Japan) equipped with a 100× 
objective and a charge-coupled device (CCD) camera (Cool SNAP 
HQ/OL; Photometrics, Tucson, AZ) or confocal microscope 
(3i Spinning Disk Confocal; Carol Zeiss, Jena Germany) equipped 
with Photometrics Evolve 512, back-illuminated electron-multi-
plying CCD. Images were analyzed using MetaMorph (Olympus) 
and ImageJ software (National Institutes of Health, Bethesda, 
MD). For Gap1-GFP localization, prototrophic cells were cultured 
to early log phase and washed twice with SD-N media supple-
mented with 10 mM urea. The washed cells were resuspended in 
the same urea media and cultured for 2 h. The fluorescence sig-
nals were observed by a Zeiss AxioImager Z1 microscope 
equipped with an AxioCam MRm camera. Images were analyzed 
using ImageJ software. All images are based on observations of 
∼100 cells. PM signal of Gap1-GFP was quantified from at least 
50 cells by ImageJ.
Analysis of sphingolipids
In vivo labeling of sphingolipids by [3H]serine or [3H]DHS was per-
formed as described in Zanolari et al. (2000) with minor modifica-
tion. In brief, 2.5 OD units of cells were treated with drugs for 1 h 
and labeled with 20 μCi of [3H]serine or 4 μCi of [3H]DHS for 30 min. 
The labeling was stopped by adding final concentration of 10 mM 
sodium azide and sodium fluoride. The cells were washed three 
times with ice-cold water, and lipids were extracted with chloroform/
methanol/water (CMW; 10:10:3) by vortexing with glass beads. The 
crude lipid extracts were dried up by N2 gas and subjected to mild 
alkaline treatment with NaOH. The lipid mixture was neutralized 
with acetic acid and dried up by N2 gas. The lipids were resus-
pended in water-saturated n-butanol and desalted with water. The 
water phase was reextracted with the water-saturated n-butanol, 
and the combined butanol phase was dried up by N2 gas. The lipids 
were resuspended in CMW and separated by TLC. The TLC plates 
were developed in chloroform/methanol/4.2 N ammonium solution 
(9:7:2). The TLC plates were exposed to a tritium-sensitive imaging 
roles in the aforementioned ORM-related diseases, which may 
lead to new applications for drugs that target the mTOR pathway 
(Benjamin et al., 2011).
MATERIALS AND METHODS
Yeast strains, plasmids, growth conditions, chemicals, 
and antibodies
Yeast strains and plasmids used in this study are listed in Supple-
mental Tables S1 and S2, respectively. Gene deletions and modifica-
tions were performed by standard PCR-based methods (Longtine 
et al., 1998). The functional FLAG- or hemagglutinin (HA)-tagged 
ORM genes were cloned from previously described strains (Breslow 
et al., 2010). Point mutations were introduced by a reverse-PCR 
method, and DNA sequences were verified. Yeast cells were grown 
in standard SD medium (6.7 g of yeast nitrogen base without amino 
acids [US Biological, Swampscott, MA] containing 20 g/l glucose) 
with appropriate nutrients to maintain plasmids. For nitrogen starva-
tion, SD-N medium (1.7 g of Difco yeast nitrogen base without 
amino acids and ammonium sulfate [BD Biosciences, San Diego, 
CA] and 20 g/l glucose) was used. For Gap1 experiments, 10 mM 
urea was supplemented in SD-N medium as nitrogen source. Phos-
tag (Wako, Richmond, VA) was prepared as indicated in the instruc-
tion manual. Rapamycin (LC Laboratories, Woburn, MA) was dis-
solved in ethanol (10% Tween-20) or dimethyl sulfoxide (DMSO). 
Cycloheximide (Calbiochem, La Jolla, CA) was dissolved in DMSO. 
Myriocin/ISP-1 (Sigma-Aldrich, St. Louis, MO) was dissolved in 
methanol. Antibodies are as follows: anti-FLAG (M2, Sigma-Aldrich), 
anti-HA (Cell Signaling Technology, Beverly, MA), anti-Pgk1 (Life 
Technologies, Carlsbad, CA), anti-actin (Millipore, Billerica, MA), 
anti–glutathione S-transferase (GST; GE Healthcare, Piscataway, NJ), 
anti-Pma1 (Santa Cruz Biotechnology, Santa Cruz, VA), anti-Gap1 
(a kind gift from Bruno André, Université Libre de Bruxelles, 
Brussels, Belgium), anti-Pep12 (Life Technologies), HRP-conjugated 
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method was run, so that the five most intense precursors were 
selected for fragmentation. The MS/MS spectra were then 
searched against SwissProt data bank using Mascot software. The 
data bank was searched with 10-ppm precursor ion tolerance, and 
the fragment ions were set to 0.6-Da tolerance. Postfiltering was 
set to a false discovery rate of 0.01. All spectra corresponding to 
phosphopeptides were manually validated.
Purification of recombinant Orm proteins from 
Escherichia coli
BL21 cells harboring pGEX-6P-1–based plasmids were cultured in 
LB media to OD = 0.6 at 37ºC, and the expression of N-terminal 
truncated Orm proteins was induced by 1 mM of isopropyl-β-d-
thiogalactopyranoside for 6 h. GST fusion proteins were purified by 
using glutathione Sepharose 4B, eluted by glutathione, and dia-
lyzed against TBS.
In vitro kinase assay of GST-Npr1
GST-Npr1 and -Npr1-K467R (kinase dead) were purified from ra-
pamycin-treated yeast cells as described in Gander et al. (2008). In 
vitro kinase reaction was performed in 50 μl consisting of 50 mM 
Tris-HCl, pH 7.2, 2 mM MnCl2, 400 μM ATP, and 100 kBq [γ-32P]ATP 
(Amersham Bio-Sciences, Piscataway, NJ). After incubation at 37ºC 
for 30 min, the reaction was stopped by adding 12.5 μl of 5× SDS 
sample buffer, and the sample was incubated at 65ºC for 10 min. 
The proteins were separated by two acryl amide gels. One gel was 
transferred to nitrocellulose membrane for immunodetection, and 
the other gel was autoradiographed with an imaging plate (Fujifilm, 
Tokyo, Japan), and the image was scanned on a Typhoon instrument 
(GE Healthcare Science).
Subcellular fractionation
Subcellular fractionation assay was performed as described in 
Kaiser et al. (2002) with minor modifications. In brief, logarithmically 
growing cells in SD media were washed twice with and resuspended 
in SD-N medium supplemented with 10 mM urea. After 2 h in cul-
ture, cells were harvested by centrifugation and washed once with 
washing buffer (10 mM sodium azide, 10 mM potassium fluoride, 
50 mM Tris-HCl, pH 7.5) and once with STE10 buffer (10% [wt/wt] 
sucrose, 10 mM Tris-HCl, pH 7.5, 10 mM EDTA). The washed cells 
were resuspended in the STE10 buffer with protease inhibitor cock-
tail and lysed with glass beads. The unbroken cells and debris were 
removed by centrifugation, and the supernatants were layered on 
the top of 20–60% (wt/wt) sucrose gradient in 10 mM Tris-HCl, 
pH 7.5, 10 mM EDTA. Samples were centrifuged for 17 h at 4ºC at 
100,000 × g in an AH-650 rotor (Thermo Scientific). Fractions were 
collected from the top of the gradient by a fraction collector. For 
immunoblot, the collected fractions were solubilized with sample 
buffer at 37ºC for 1 h.
Citrulline uptake assays
Citrulline uptake assay was performed as described in Roberg 
et al. (1997). Briefly, logarithmically growing cells were washed 
twice with SD-N media supplemented with 10 mM urea and resus-
pended in the same urea media. Cells were further cultured for 2 h. 
To initiate an assay, 20 μM [14C]citrulline was added to cell suspen-
sion, and 100-μl aliquots were removed and immediately filtered 
every 30 s up to a total of 2.5 min. Cells were washed three times 
with 10 ml of ice-cold doubly distilled H2O and placed in scintilla-
tion fluid to determine cellular incorporation of [14C]citrulline. The 
relative rate of [14C]citrulline uptake was calculated from three in-
dependent experiments.
plate (Fujifilm, Tokyo, Japan) for 3–5 d, and the radioactivity was 
scanned with a Typhoon scanner (GE Healthcare, Piscataway, NJ). 
The abundance of sphingolipids was quantified from at least three 
independent experiments by using ImageJ.
SPT assay
SPT assays were carried out by the method of Rutti et al., (2009). 
Yeast cell lysates were prepared in 50 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES; pH 8.3), 1 mM EDTA, and 
0.1% sucrose monolaurate (Sigma-Aldrich) by a Fastprep (45 s × 5; 
3-min interval on ice) at 4°C with glass beads.
Purification of FLAG-tagged proteins
Purification of FLAG-tagged proteins was performed as described 
in Breslow et al. (2010) with small modification. In brief, logarithmi-
cally growing yeast cells (500–750 OD units) were harvested, washed 
in cold water, and resuspended in immunoprecipitation buffer 
(50 mM HEPES-KOH, pH 6.8, 150 mM KOAc, 2 mM MgOAc, 1 mM 
CaCl2, 15% glycerol) with 0.1% water-soluble digitonin (Biosynth, 
Staad, Switzerland), PPi, and Pi. Cell lysates were prepared as de-
scribed, followed by addition of equal volume of immunoprecipita-
tion buffer with 1.9% digitonin, PPi, and Pi. Membrane proteins 
were solubilized by incubating lysates at 4ºC for 45 min. Unsolubi-
lized material and unbroken cells were removed by ultracentrifuga-
tion at 100,000 × g for 1 h. Clarified lysates were incubated with 
anti-FLAG resin (Sigma-Aldrich) for 2.5 h. The anti-FLAG beads were 
then washed with 1 ml of immunoprecipitation buffer containing 
0.1% digitonin, and bound proteins were eluted by addition of im-
munoprecipitation buffer with 0.25% digitonin and 1 mg/ml 3× 
FLAG peptide (Sigma-Aldrich).
Phosphomapping of Orm proteins
Purified FLAG-tagged Orm1 and Orm2 were reduced with 10 mM 
dithiothreitol in 100 mM Tris-HCl, pH 8.0, and 6 M urea for 60 min 
at 37°C and alkylated with 50 mM iodoacetamide for 15 min in 
the dark. FLAG-tagged Orm1 and Orm2 were digested with 
500 ng of endoproteinase LysC (lysylendopeptidase; Wako) for 
2 h. The digest was diluted with 100 mM Tris-HCl, pH 8.0, to lower 
the urea concentration to 2 M. The endoprotein LysC (ELC) digest 
was further digested with 500 ng of trypsin (sequencing grade 
modified; Promega, Madison, WI) overnight at 37°C. Digestion 
was stopped with trifluoroacetic acid (TFA) to 1% final concentra-
tion, and the peptides were desalted on a MicroSpin C18 car-
tridge (The Nest Group, Southborough, MA). Bound peptides 
were eluted with 80% acetonitrile/0.1% TFA and dried in a Speed-
Vac for subsequent analysis. The peptides were dissolved in 50 μl 
of 0.1% TFA, and 2 μl was analyzed by capillary liquid chromatog-
raphy tandem mass spectrometry (MS/MS) using a setup of a trap-
ping ProteoCol C-18 column (0.15 × 10 mm; SGE Analytical 
Science, Austin, TX) and a separating column (0.1 mm × 10 cm) 
that had been packed with Magic 300-Å C18 reverse-phase mate-
rial (5-μm particle size; Michrom Bioresources/Bruker-Michrom, 
Auburn, CA). The columns were connected on-line to an Orbitrap 
FT hybrid instrument (Thermo Scientific). A linear gradient from 2 
to 80% solvent B (0.1% acetic acid and 80% acetonitrile in water) 
in solvent A (0.1% acetic acid and 2% acetonitrile in water) 
in 85 min was delivered with an Agilent 1200 pump (Agilent 
Technologies, Santa Clara, CA) at a flow rate of 300 nl/min. The 
eluting peptides were ionized at 1.7 kV. The mass spectrometer 
was operated in a data-dependent manner. The precursor scan 
was done in the Orbitrap set to 60,000 resolution, and the frag-
ment ions were mass analyzed in the LTQ instrument. A top-five 
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